JP7862331B2 - GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 - Google Patents
GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用Info
- Publication number
- JP7862331B2 JP7862331B2 JP2022580238A JP2022580238A JP7862331B2 JP 7862331 B2 JP7862331 B2 JP 7862331B2 JP 2022580238 A JP2022580238 A JP 2022580238A JP 2022580238 A JP2022580238 A JP 2022580238A JP 7862331 B2 JP7862331 B2 JP 7862331B2
- Authority
- JP
- Japan
- Prior art keywords
- xyl
- rha
- fuc
- saponin
- glc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026073994A JP2026126321A (ja) | 2020-06-24 | 2026-04-27 | GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025902 | 2020-06-24 | ||
| NL2025902 | 2020-06-24 | ||
| PCT/NL2021/050384 WO2021261992A1 (en) | 2020-06-24 | 2021-06-18 | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
| NLPCT/NL2021/050384 | 2021-06-18 | ||
| PCT/NL2021/050394 WO2021261998A1 (en) | 2020-06-24 | 2021-06-23 | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026073994A Division JP2026126321A (ja) | 2020-06-24 | 2026-04-27 | GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533693A JP2023533693A (ja) | 2023-08-04 |
| JP2023533693A5 JP2023533693A5 (cg-RX-API-DMAC10.html) | 2024-07-01 |
| JP7862331B2 true JP7862331B2 (ja) | 2026-05-19 |
Family
ID=72087123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580238A Active JP7862331B2 (ja) | 2020-06-24 | 2021-06-23 | GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 |
| JP2026073994A Pending JP2026126321A (ja) | 2020-06-24 | 2026-04-27 | GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026073994A Pending JP2026126321A (ja) | 2020-06-24 | 2026-04-27 | GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230293562A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4596052A3 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7862331B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230044196A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116194148A (cg-RX-API-DMAC10.html) |
| IL (1) | IL299349A (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026060043A1 (en) * | 2024-09-10 | 2026-03-19 | Xact Bio, Inc. | Compositions and methods for targeting a tissue specific protein expression |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015071388A1 (en) | 2013-11-14 | 2015-05-21 | Roche Innovation Center Copenhagen A/S | Apob antisense conjugate compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2522213A1 (en) * | 2003-04-08 | 2004-10-28 | Dante J. Marciani | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
| WO2011054811A1 (en) * | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| US20220023433A1 (en) * | 2018-12-21 | 2022-01-27 | Sapreme Technologies B.V. | Saponin Conjugates |
-
2021
- 2021-06-23 EP EP25178184.5A patent/EP4596052A3/en active Pending
- 2021-06-23 KR KR1020237002644A patent/KR20230044196A/ko active Pending
- 2021-06-23 JP JP2022580238A patent/JP7862331B2/ja active Active
- 2021-06-23 CN CN202180052532.8A patent/CN116194148A/zh active Pending
- 2021-06-23 EP EP21734544.6A patent/EP4171643B1/en active Active
- 2021-06-23 IL IL299349A patent/IL299349A/en unknown
- 2021-06-23 US US18/012,778 patent/US20230293562A1/en active Pending
-
2026
- 2026-04-27 JP JP2026073994A patent/JP2026126321A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015071388A1 (en) | 2013-11-14 | 2015-05-21 | Roche Innovation Center Copenhagen A/S | Apob antisense conjugate compounds |
Non-Patent Citations (2)
| Title |
|---|
| Biomedicines,2017年,Vol.5, No.14,pp.1-25 |
| Molecular Therapy: Nucleic acids,2019年,Vol.14,pp. 67-79 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4596052A2 (en) | 2025-08-06 |
| EP4596052A3 (en) | 2025-11-05 |
| EP4171643C0 (en) | 2025-06-04 |
| JP2026126321A (ja) | 2026-08-04 |
| EP4171643A1 (en) | 2023-05-03 |
| US20230293562A1 (en) | 2023-09-21 |
| KR20230044196A (ko) | 2023-04-03 |
| JP2023533693A (ja) | 2023-08-04 |
| IL299349A (en) | 2023-02-01 |
| EP4171643B1 (en) | 2025-06-04 |
| CN116194148A (zh) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4171641B1 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| WO2022055351A1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| JP2024530839A (ja) | サポニン、オリゴヌクレオチド、およびGalNAcの複合体 | |
| WO2021261998A1 (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| JP2011500002A (ja) | Rna干渉効果が高い脂質修飾2本鎖rna | |
| EP4171643B1 (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| EP4210760B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2021295358B2 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| HK40128805A (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| HK40116734A (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate | |
| HK40129944A (zh) | Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物 | |
| HK40124033A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| CN117881427A (zh) | 皂苷、寡核苷酸和galnac的缀合物 | |
| HK40110483B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2021339332A1 (en) | Conjugate of saponin, oligonucleotide and GalNAc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7862331 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |